Common use of Additional Targets Clause in Contracts

Additional Targets. (a) The Parties agree that [*] Additional Targets shall be selected for screening under the Research Collaboration. The process for selection of such Additional Targets will be as follows: (i) through the JRC, the Parties will nominate a group of potential Targets for evaluation of suitability for GEMS, and each Party shall provide to the other Party the information specified in Section 3.11(a)(ii); [*] Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. (ii) the nominated Target candidates will be evaluated by PTC in order to determine the potential for modulating said Target candidates utilizing GEMS; (iii) PTC will submit to the JRC a ranked list of the nominated Target candidates along with any literature or experimental evidence, as known at the time of submission; (iv) the JRC will analyze the nominated Target candidates evaluated by PTC and determine which of these Target candidates will be selected as Additional Targets based on the information provided in subsection 3.4(a)(iii); (v) if the JRC selects any of the Target candidates to be Additional Targets, the JRC under Section 2.2(b)(iv) will submit such recommendation and the proposed definition of “Active” to the JMC for written approval under Section 2.3(c)(ii); and (vi) once approved by the JMC under Section 2.3(c)(ii), the Additional Targets will be screened in the manner described in the Research Plan using the definition of “Active” approved by the JMC. (b) The Parties agree that the JRC will select the Additional Targets within [*] months after the Effective Date. Using the same process set forth in Section 3.4(a), the JRC may select and the JMC may approve one or more substitute Target(s) in replacement of any previously selected Target prior to the commencement of Lead Optimization against such previously selected Target. If one or more substitute Target(s) are selected, it is understood that (i) additional FTEs may be required to complete work on these latter Targets, and (ii) the provisions of Section 3.11 shall no longer apply to the previously selected Target that has been replaced.

Additional Targets. (a) The Parties agree If, during the applicable Pathway Designation Term, OncoMed is interested in pursuing with any Third Party a potential target that, based upon [***] OncoMed believes may be in the [***] Pathway or the RSPO-LGR Pathway, it shall issue a notice to Celgene that it wishes [***] to determine in accordance with Section 2.2.9 whether or not such potential target is within the [***] Pathway or RSPO-LGR Pathway, as applicable, provided that subject to Section 2.2.8(b), for a period of [***] following the Effective Date OncoMed may not issue such a notice to Celgene, and may not add such potential target to the Excluded Target List, unless Celgene agrees in writing that such target can be considered an Excluded Target. If [***] such potential target is within the [***] Pathway, or the RSPO-LGR Pathway, as applicable, then OncoMed shall promptly notify Celgene in writing of such potential target, and such potential target shall be added to Exhibit C-1 or C-2 of this Agreement, as applicable, and shall be a RSPO Umbrella Target, or a [***] Umbrella Target, as applicable. If [***] such potential target is not within either the [***] Pathway or the RSPO-LGR Pathway, then such potential target shall not be added to Exhibit C-1 or C-2 of this Agreement and shall not be deemed a RSPO Umbrella Target, or a [***] Umbrella Target, and such potential target shall be an Excluded Target and shall be added to the Excluded Target List. (b) Notwithstanding Section 2.2.8(a), if, at any time during the applicable Pathway Designation Term, if OncoMed is required to [***] rights to any target (including a target that may be a potential target in the [***] Pathway or the RSPO-LGR Pathway) under the [***] (such target, a “[***] Additional Targets Target”), then OncoMed shall be selected for screening under the Research Collaboration. The process for selection provide written notice of such [***] Additional Targets will be as follows: (i) through the JRC, the Parties will nominate a group of potential Targets for evaluation of suitability for GEMS, and each Party shall provide Target to the other Party the information specified in Section 3.11(a)(ii); Gatekeeper, along with a notation that such target is an Excluded Target because it is a [***] Additional Target. Upon receipt of [***] Certain information on in this page document has been redacted omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. (ii) . such written notice by the nominated Gatekeeper, such [***] Additional Target candidates will shall be evaluated by PTC in order deemed an Excluded Target, and shall be automatically added to the Excluded Target List. In conjunction with provision of notice to the Gatekeeper, OncoMed shall provide written notice to Celgene that it has added a target to the Excluded Target List. If Celgene desires to determine whether such [***] Additional Target may be a target in the [***] Pathway or the RSPO Pathway, it shall issue a notice to OncoMed that it wishes [***] to determine in accordance with Section 2.2.9 whether or not such potential for modulating said target is within the [***] Pathway or RSPO-LGR Pathway. Whether or not [***] such [***] Additional Target candidates utilizing GEMS; (iii) PTC will submit to is within the JRC a ranked list of [***] Pathway, or the nominated Target candidates along with any literature or experimental evidenceRSPO-LGR Pathway, as known at the time of submission; (iv) the JRC will analyze the nominated applicable, such [***] Additional Target candidates evaluated by PTC and determine which of these Target candidates will be selected as Additional Targets based shall remain on the information provided in subsection 3.4(a)(iii); (v) Excluded Target List, but if [***] such [***] Additional Target is within the JRC selects any of [***] Pathway or the RSPO-LGR Pathway, then [***] such [***] Additional Target candidates to be Additional Targets, placed on the JRC under Section 2.2(b)(iv) will submit such recommendation and Excluded Target List during the proposed definition of “Active” to the JMC for written approval under Section 2.3(c)(ii); and (vi) once approved by the JMC under Section 2.3(c)(ii), the Additional Targets will be screened Pathway Designation Term that is [***] in the manner described in the Research Plan using the definition of “Active” approved by the JMC. (b) The Parties agree that the JRC will select the Additional Targets within [***] months after Pathway, or the Effective Date. Using the same process set forth in Section 3.4(a)RSPO-LGR Pathway, the JRC may select and the JMC may approve one or more substitute Target(s) in replacement of any previously selected Target prior to the commencement of Lead Optimization against such previously selected Target. If one or more substitute Target(s) are selected, it is understood that (i) additional FTEs may be required to complete work on these latter Targets, and (ii) the provisions of Section 3.11 shall no longer apply to the previously selected Target that has been replacedas applicable.